CN115335076B - 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法 - Google Patents
编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法Info
- Publication number
- CN115335076B CN115335076B CN202180019813.3A CN202180019813A CN115335076B CN 115335076 B CN115335076 B CN 115335076B CN 202180019813 A CN202180019813 A CN 202180019813A CN 115335076 B CN115335076 B CN 115335076B
- Authority
- CN
- China
- Prior art keywords
- leu
- seq
- pro
- arg
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202511456350.3A CN121221754A (zh) | 2020-01-09 | 2021-01-08 | 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法 |
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062958827P | 2020-01-09 | 2020-01-09 | |
| US202062958809P | 2020-01-09 | 2020-01-09 | |
| US62/958,809 | 2020-01-09 | ||
| US62/958,827 | 2020-01-09 | ||
| US202062967242P | 2020-01-29 | 2020-01-29 | |
| US202062967104P | 2020-01-29 | 2020-01-29 | |
| US62/967,242 | 2020-01-29 | ||
| US62/967,104 | 2020-01-29 | ||
| US202063064506P | 2020-08-12 | 2020-08-12 | |
| US202063064571P | 2020-08-12 | 2020-08-12 | |
| US63/064,571 | 2020-08-12 | ||
| US63/064,506 | 2020-08-12 | ||
| US202063112202P | 2020-11-11 | 2020-11-11 | |
| US202063112219P | 2020-11-11 | 2020-11-11 | |
| US63/112,202 | 2020-11-11 | ||
| US63/112,219 | 2020-11-11 | ||
| PCT/US2021/012630 WO2021142212A1 (en) | 2020-01-09 | 2021-01-08 | Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202511456350.3A Division CN121221754A (zh) | 2020-01-09 | 2021-01-08 | 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115335076A CN115335076A (zh) | 2022-11-11 |
| CN115335076B true CN115335076B (zh) | 2025-10-28 |
Family
ID=74505354
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180019813.3A Active CN115335076B (zh) | 2020-01-09 | 2021-01-08 | 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法 |
| CN202511456350.3A Pending CN121221754A (zh) | 2020-01-09 | 2021-01-08 | 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202511456350.3A Pending CN121221754A (zh) | 2020-01-09 | 2021-01-08 | 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US12605444B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4087605A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7696909B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220163354A (cg-RX-API-DMAC7.html) |
| CN (2) | CN115335076B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021205936A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022013620A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3166989A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294387A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022008572A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12022551648A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021142212A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202310905B (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115335076B (zh) * | 2020-01-09 | 2025-10-28 | 病毒治疗有限责任公司 | 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法 |
| WO2026093412A2 (en) * | 2024-10-29 | 2026-05-07 | Nec Oncoimmunity As | Hbv vaccine |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107074913A (zh) * | 2014-06-23 | 2017-08-18 | 巴斯德研究院 | 包含非结构蛋白的片段的登革热病毒嵌合多表位及其在抗登革热病毒感染的免疫原性组合物中的用途 |
| CN109414496A (zh) * | 2016-04-06 | 2019-03-01 | 华盛顿大学 | 用于乙型肝炎病毒(hbv)的使用hbv核心抗原的治疗性疫苗 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005012502A2 (en) | 2003-03-28 | 2005-02-10 | Idm Pharma, Inc. | Methods of identifying optimal variants of peptide epitopes |
| US20090246220A1 (en) * | 2006-08-28 | 2009-10-01 | Ertl Hildegund C J | Constructs for enhancing immune responses |
| PE20140844A1 (es) | 2011-02-12 | 2014-07-14 | Globeimmune Inc | Terapeuticos a base de levadura para infeccion de la hepatitis b cronica |
| GB201223386D0 (en) * | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| CN105367662B (zh) * | 2014-08-29 | 2021-03-12 | 汤正好 | 一种hbv相关的融合蛋白、其制备方法及其应用 |
| EP3490610A4 (en) | 2016-08-01 | 2020-05-20 | The Wistar Institute Of Anatomy And Biology | COMPOSITIONS AND METHODS FOR REPLICATION-DEFICIENT ADENOVIRAL VECTORS FOR VACCINE APPLICATIONS |
| HRP20241379T1 (hr) * | 2019-09-30 | 2024-12-20 | Gilead Sciences, Inc. | Cjepiva za hbv i postupci za liječenje hbv |
| CN115335076B (zh) * | 2020-01-09 | 2025-10-28 | 病毒治疗有限责任公司 | 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法 |
-
2021
- 2021-01-08 CN CN202180019813.3A patent/CN115335076B/zh active Active
- 2021-01-08 EP EP21703111.1A patent/EP4087605A1/en active Pending
- 2021-01-08 BR BR112022013620A patent/BR112022013620A2/pt unknown
- 2021-01-08 IL IL294387A patent/IL294387A/en unknown
- 2021-01-08 PH PH1/2022/551648A patent/PH12022551648A1/en unknown
- 2021-01-08 JP JP2022542413A patent/JP7696909B2/ja active Active
- 2021-01-08 CN CN202511456350.3A patent/CN121221754A/zh active Pending
- 2021-01-08 MX MX2022008572A patent/MX2022008572A/es unknown
- 2021-01-08 CA CA3166989A patent/CA3166989A1/en active Pending
- 2021-01-08 KR KR1020227027069A patent/KR20220163354A/ko active Pending
- 2021-01-08 AU AU2021205936A patent/AU2021205936A1/en active Pending
- 2021-01-08 WO PCT/US2021/012630 patent/WO2021142212A1/en not_active Ceased
- 2021-01-08 US US17/790,259 patent/US12605444B2/en active Active
- 2021-08-27 US US17/459,313 patent/US11291716B2/en active Active
-
2022
- 2022-02-24 US US17/679,356 patent/US11850282B2/en active Active
-
2023
- 2023-10-24 US US18/492,945 patent/US12290561B2/en active Active
- 2023-11-27 ZA ZA2023/10905A patent/ZA202310905B/en unknown
-
2025
- 2025-04-04 US US19/170,785 patent/US20250228934A1/en active Pending
- 2025-06-11 JP JP2025097871A patent/JP2025124904A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107074913A (zh) * | 2014-06-23 | 2017-08-18 | 巴斯德研究院 | 包含非结构蛋白的片段的登革热病毒嵌合多表位及其在抗登革热病毒感染的免疫原性组合物中的用途 |
| CN109414496A (zh) * | 2016-04-06 | 2019-03-01 | 华盛顿大学 | 用于乙型肝炎病毒(hbv)的使用hbv核心抗原的治疗性疫苗 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4087605A1 (en) | 2022-11-16 |
| MX2022008572A (es) | 2022-09-23 |
| JP7696909B2 (ja) | 2025-06-23 |
| US12605444B2 (en) | 2026-04-21 |
| BR112022013620A2 (pt) | 2022-09-13 |
| AU2021205936A1 (en) | 2022-07-21 |
| IL294387A (en) | 2022-08-01 |
| US20230063089A1 (en) | 2023-03-02 |
| US20240091347A1 (en) | 2024-03-21 |
| ZA202310905B (en) | 2025-06-25 |
| US20250228934A1 (en) | 2025-07-17 |
| KR20220163354A (ko) | 2022-12-09 |
| US12290561B2 (en) | 2025-05-06 |
| JP2025124904A (ja) | 2025-08-26 |
| JP2023510544A (ja) | 2023-03-14 |
| CA3166989A1 (en) | 2021-07-15 |
| WO2021142212A1 (en) | 2021-07-15 |
| CN121221754A (zh) | 2025-12-30 |
| US11291716B2 (en) | 2022-04-05 |
| US20220175913A1 (en) | 2022-06-09 |
| US11850282B2 (en) | 2023-12-26 |
| PH12022551648A1 (en) | 2024-02-12 |
| US20210393770A1 (en) | 2021-12-23 |
| CN115335076A (zh) | 2022-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230330215A1 (en) | Sars-cov-2 vaccines | |
| JP2022166122A (ja) | 非標準的なcd8+t細胞応答を生成するのに有用な方法および組成物 | |
| US20250228934A1 (en) | Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same | |
| Kosinska et al. | DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model | |
| CN114340661A (zh) | Hiv抗原和mhc复合物 | |
| US20250121052A1 (en) | Sars-cov-2 vaccines | |
| Ragonnaud et al. | Therapeutic vaccine against primate papillomavirus infections of the cervix | |
| CA3079776A1 (en) | A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition | |
| Nemirov et al. | Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses | |
| Ragonnaud et al. | Breadth of T cell responses after immunization with adenovirus vectors encoding ancestral antigens or polyvalent papillomavirus antigens | |
| HK40082959A (en) | Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same | |
| Tan et al. | Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens | |
| Tan et al. | Construction and efficacy testing of DNA vaccines containing HLA-A* 02: 01-restricted SARS-CoV-2 T-cell epitopes predicted by immunoinformatics: DNA vaccines containing HLA-A* 02: 01-restricted SARS-CoV-2 T-cell epitopes | |
| Lasaro et al. | Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques | |
| Li et al. | Protection against SHIV‐KB9 Infection by Combining rDNA and rFPV Vaccines Based on HIV Multiepitope and p24 Protein in Chinese Rhesus Macaques | |
| Escarra-Senmarti et al. | A conserved region T-cell vaccine for Sarbecoviruses | |
| Tagaram et al. | An SV40 VP1-derived epitope recognized by CD8+ T cells is naturally processed and presented by HLA-A⁎ 0201 and cross-reactive with human polyomavirus determinants | |
| EP4408462A2 (en) | Pancoronavirus vaccines | |
| Janack | Immunogenicity of Epigraph Antigens in Vaccination against SARS-COV-2 in Mice | |
| CN118302195A (zh) | 泛冠状病毒疫苗 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40082959 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |